Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (<i>n</i> = 130) versus 4-weekly (once every 4 weeks) (<i>n</i> = 133) BTA dosing for metastatic breas...

Full description

Bibliographic Details
Main Authors: Megan M. Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond, Dean Fergusson, Terry L. Ng, Kednapa Thavorn
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Current Oncology
Subjects:
cost-effectiveness
bone metastasis
denosumab
pamidronate
zoledronate
breast cancer
Online Access:https://www.mdpi.com/1718-7729/28/3/171

Internet

https://www.mdpi.com/1718-7729/28/3/171

Similar Items